Compare
X4 Pharmaceuticals, Inc vs Editas Medicine, Inc. vs Fennec Pharmaceuticals Inc. vs Alector, Inc.
| Latest fiscal year | X4 Pharmaceuticals, Inc XFOR | Editas Medicine, Inc. EDIT | Fennec Pharmaceuticals Inc. FENC | Alector, Inc. ALEC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $35.11M | $40.52M | $44.64M | $21.05M |
| Revenue growth (YoY) | n/m | +25.4% | -6.1% | -79.1% |
| Gross margin | 83.6% (computed) | n/a | n/a | n/a |
| Operating margin | -247.4% | -394.9% | -14.1% | -741.3% |
| Net margin | -225.6% | -395.0% | -21.8% | -679.2% |
| Net income | -$79.20M | -$160.06M | -$9.74M | -$142.93M |
| EPS (Diluted) | -$1.87 | -$1.80 | -$0.34 | -$1.39 |
| Operating cash flow | -$85.62M | -$165.24M | -$12.47M | -$184.03M |
| Free cash flow | -$85.62M | -$165.85M | n/a | -$184.07M |
| Cash & equivalents | $217.05M | $146.65M | $36.79M | $65.80M |
| Total assets | $290.46M | $186.53M | $70.55M | $293.24M |
| Total liabilities | $104.17M | $159.25M | $35.08M | $262.59M |
| Shareholders' equity | $186.29M | $27.29M | $35.47M | $30.65M |
| Return on year-end equity | -42.5% | -586.6% | -27.5% | -466.3% |
| Shares outstanding | 90.91M | 97.87M | 34.16M | 110.36M |
Revenue, most recent five fiscal years
| Fiscal year | X4 Pharmaceuticals, Inc | Editas Medicine, Inc. | Fennec Pharmaceuticals Inc. | Alector, Inc. |
|---|---|---|---|---|
| Latest | $35.11M Ended 2025-12-31 | $40.52M Ended 2025-12-31 | $44.64M Ended 2025-12-31 | $21.05M Ended 2025-12-31 |
| 1 year earlier | $2.56M Ended 2024-12-31 | $32.31M Ended 2024-12-31 | $47.54M Ended 2024-12-31 | $100.56M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $78.12M Ended 2023-12-31 | $21.25M Ended 2023-12-31 | $97.06M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $19.71M Ended 2022-12-31 | $1.53M Ended 2022-12-31 | $133.62M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $25.54M Ended 2021-12-31 | n/a | $207.09M Ended 2021-12-31 |